| Message: | Use: it is a development of the phosphodiesterase type 5 inhibitors, for the treatment of male sexual dysfunction, at present in the America, EU and Japan have completed phase II clinical trials, phase III clinical trials will start. The product is composed of Japanese Tanabe Pharma Company and VIVUS company development. In addition to oral dosage forms, VIVUS company is also developing Avanafil urethral administration, for not responding to oral dosage forms of patients. Avanafil is a potent, highly selective phosphodiesterase 5 inhibitor, |
my account
